Skip to content

US · HCM · DRUG MANUFACTURERS - SPECIALTY & GENERIC

HUTCHMED (China) Limited (HCM) intrinsic value and stock valuation

$13.22as of 2026-11-21 · Mkt cap 2.02B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

HUTCHMED (China) Limited DCF and intrinsic value

InvestorsCraft values HCM with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from HCM’s statements →

HUTCHMED (China) Limited Graham Number

Graham Number: $20.92d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Hong Kong hutch-med.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$550M+19.3% 5y CAGRd
20112025
Net income
$458.1M
20112025
Free cash flow
-$-88.81M
20112025
Total equity
$1.25B+19.2% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$550M$630.2M$838M$426.4M$356.1M
Operating income-$-54.73M-$-43.7M$18.4M-$-409.77M-$-328.32M
Net income$458.1M$37.7M$100.8M-$-360.83M-$-194.65M
EPSd$2.62M$216.1K$579.7K-$-2.13M-$-1.23M
Operating cash flow-$-64.66M$500K$219.3M-$-268.6M-$-204.22M
Capital expenditure-$-24.15M-$-17.93M-$-32.61M-$-36.66M-$-16.76M
Free cash flow-$-88.81M-$-17.44M$186.7M-$-305.26M-$-220.98M
Total assets$1.75B$1.27B$1.28B$1.03B$1.37B
Total debt$97.9M$89.8M$86.1M$27M$39M
Net debt$26.6M-$-64.14M-$-197.46M-$-286.27M-$-338.56M
Total equity$1.25B$771.9M$743.4M$636.9M$1.04B
Cash and short-term investments$1.37B$836.1M$886.3M$631M$1.01B
Income statement
20252024202320222021
Revenue$550M$630.2M$838M$426.4M$356.1M
Cost of revenue$337.2M$347.6M$384.5M$311.1M$258.2M
Gross profit$212.7M$282.6M$453.6M$115.3M$97.9M
Research and development expenses$164.2M$213.4M$303.1M$267.6M$207.5M
Selling, general and administrative expenses$103.3M$112.9M$133.2M$136.1M$127.1M
Other expenses$0.00$0.00$0.00$119.3M$91.6M
Operating expenses$267.5M$326.3M$436.2M$523M$426.2M
Cost and expenses$604.7M$673.9M$819.6M$834.1M$684.5M
Interest income$50M$40.1M$36.2M$9.6M$2.08M
Interest expense$2.87M$2.87M$760K$650K$590K
Depreciation and amortization$13.3M$12.3M$8.21M$8.66M$7.19M
Ebitda-$-41.38M-$-31.36M$26.6M-$-401.11M-$-207.96M
Operating income-$-54.73M-$-43.7M$18.4M-$-409.77M-$-328.32M
Total other income/expenses, net$577.5M$89.1M$87.2M$51.5M$173.2M
Income before tax$522.7M$45.4M$105.6M-$-360.24M-$-155.33M
Income tax expense$63.8M$7.19M$4.51M-$-280K$11.9M
Net income$458.1M$37.7M$100.8M-$-360.83M-$-194.65M
Weighted average shares outstanding$171.7M$171.1M$169.9M$169.4M$158.5M
Weighted average diluted shares outstanding$174.6M$174.6M$173.8M$169.4M$158.5M
Balance sheet
20252024202320222021
Cash and short-term investments$1.37B$836.1M$886.3M$631M$1.01B
Net receivables$147.8M$167.7M$150.5M$126.7M$147.7M
Inventory$41.1M$50.4M$50.3M$56.7M$35.8M
Total current assets$1.57B$1.07B$1.1B$839.9M$1.21B
Property, plant and equipment, net$97.7M$97M$104.4M$84.7M$66.3M
Goodwill and intangible assets$12.1M$2.99M$3.08M$3.22M$3.54M
Long-term investments$52.3M$0.00$48.4M$73.8M-$-557.68M
Total non-current assets$185.8M$207.6M$182.9M$189.6M$160.6M
Total assets$1.75B$1.27B$1.28B$1.03B$1.37B
Accounts payable$45.5M$42.5M$36.3M$71.1M$41.2M
Short-term debt$27.9M$26.3M$35.1M$3.71M$31.8M
Deferred revenue$31.4M$0.00$57.6M$13.4M$15.6M
Total current liabilities$315.8M$376.6M$403M$353.9M$311.7M
Long-term debt$70M$63.5M$51.1M$23.3M$7.16M
Deferred revenue, non-current$20.1M$48.4M$69.5M$190K-$-2.77M
Total non-current liabilities$186.1M$125.8M$133.4M$38.7M$21.5M
Capital lease obligations$4.73M$7.01M$6.79M$5.2M$12.1M
Total liabilities$501.8M$502.3M$536.4M$392.6M$333.2M
Common stock$87.2M$87.2M$87.1M$86.5M$86.5M
Retained earnings-$-378.64M-$-833.17M-$-870.87M-$-971.48M-$-610.33M
Accumulated other comprehensive income (loss)-$-4.53M$0.00-$-8.16M-$-1.9M$5.57M
Total equity$1.25B$771.9M$743.4M$636.9M$1.04B
Total investments$1.35B$682.2M$651.2M$391.5M$76.5M
Total debt$97.9M$89.8M$86.1M$27M$39M
Net debt$26.6M-$-64.14M-$-197.46M-$-286.27M-$-338.56M
Cash flow statement
20252024202320222021
Net income$457.7M$37.7M$100.8M-$-360.39M-$-167.04M
Depreciation and amortization$13.3M$12.3M$8.21M$8.66M$7.19M
Stock-based compensation$15.3M$21.6M$36.6M$30.6M$42M
Change in working capital-$-60.86M-$-62.17M$71.2M$58.7M$32.5M
Accounts receivable$24.2M-$-41.57M-$-13.05M-$-2.38M-$-41.39M
Inventory$9.54M-$-770K$4.13M-$-21.21M-$-16M
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-64.66M$500K$219.3M-$-268.6M-$-204.22M
Investments in property, plant and equipment-$-14.15M-$-17.93M-$-32.61M-$-36.66M-$-16.76M
Acquisitions, net$608.5M$0.00-$-2.99M$320K$0.00
Net cash used for investing activities-$-29.41M-$-96.06M-$-291.14M$296.6M-$-306.32M
Common stock issued$1.58M$790K$5.09M$170K$717.3M
Common stock repurchased$0.00-$-36.06M-$-9.07M-$-48.08M-$-27.31M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$7.84M-$-30.67M$48.7M-$-82.76M$650M
Net change in cash-$-82.63M-$-129.63M-$-29.69M-$-64.26M$141.9M
Cash at end of period$71.3M$154M$283.6M$313.3M$377.5M
Operating cash flow-$-64.66M$500K$219.3M-$-268.6M-$-204.22M
Capital expenditure-$-24.15M-$-17.93M-$-32.61M-$-36.66M-$-16.76M
Free cash flow-$-88.81M-$-17.44M$186.7M-$-305.26M-$-220.98M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About HUTCHMED (China) Limited

        HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main areas: Oncology/Immunology and a segment encompassing Other Ventures. The company's reach extends from Hong Kong globally. Among its pipeline, HUTCHMED is developing Savolitinib, an inhibitor targeting non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Another key therapeutic, Fruquintinib, is an inhibitor being investigated for its efficacy in CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and a range of other gastrointestinal and solid tumors. Furthermore, the company's portfolio includes Surufatinib, an inhibitor applicable to numerous conditions such as neuroendocrine tumors (NETs - both pancreatic and non-pancreatic), biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, gastric cancer (GC), thyroid cancer, endometrial cancer (EMC), NSCLC, and general solid tumors. HMPL-523, a spleen tyrosine kinase inhibitor, is designed to treat hematological cancers and specific chronic immune conditions, while HMPL-689 targets the isoform PI3Kd (phosphoinositide 3'-kinase delta). Additional compounds in development include Tazemetostat, an EZH2 inhibitor indicated for specific epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor showing promise for hematological malignancies, gliomas, and solid tumors; HMPL-760, which functions as a Bruton's tyrosine kinase inhibitor; and HMPL-453, an inhibitor aimed at intrahepatic cholangiocarcinoma. The pipeline also features HMPL-295 for solid tumors, HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors, alongside Epitinib (HMPL-813) and Theliatinib (HMPL-309), both of which act as inhibitors. HUTCHMED maintains strategic collaboration agreements with a number of partners, including AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The entity, established in 2000 and headquartered in Central, Hong Kong, was previously identified as Hutchison China MediTech Limited before officially adopting its current name, HUTCHMED (China) Limited, in May 2021.

        CEO
        Chig Fung Cheng
        Employees
        1.8K
        Beta
        0.43

        Explore

        Frequently asked questions

        What is the intrinsic value of HUTCHMED (China) Limited (HCM)?

        InvestorsCraft does not currently publish an intrinsic value for HCM. How the IC value is calculated.

        Is HCM undervalued?

        InvestorsCraft does not publish an undervaluation signal for HCM at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.